



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
August 4, 2020

Therapeutic Class	Drug Name	DURB Recommendation
Antimigraine Agents, Other		
	<i>Nurtec ODT (Oral) Tablet</i>	P/PA
	<i>Reyvow (Oral) Tablet</i>	NP/PA
	<i>Ubrelvy (Oral) Tablet</i>	NP/PA
	<i>Vyepti (Intravenous) Injection</i>	NP/PA (for coverage on the PADL)
Duchenne Muscular Dystrophy Treatments		
	<i>Vyondys 53 (Intravenous) Injection</i>	NP/PA (for coverage on the PADL)
	<i>Exondys 51 (Intravenous) Injection</i>	NP/PA (for coverage on the PADL)
Stimulants and Related Agents		
	<i>Wakix (Oral) Tablet</i>	NP/PA

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List